Cantor Fitzgerald Starts Coverage on ArriVent Biopharma with Strong Upside
Cantor Fitzgerald initiates coverage on ArriVent Biopharma with an Overweight rating, highlighting strong Phase 3 potential and significant upside.
/ 1663 items
#XY↓
Novo Nordisk Wins FDA Approval for Wegovy Weight-Loss Pill, Beating Lilly to Market
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
FDA Approves Amneal's Denosumab Biosimilars for Bone Health
Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment.
Dogwood Therapeutics: Red Flags in Latest Trial Update
Dogwood Therapeutics' (DWTX) Phase 2b trial results reveal gaps, delayed timelines, and questions about their chemotherapy pain treatment Halneuron.
Biotech Stocks Update: ZBIO, SPRB, CNTX, OVID Ratings
Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.
Wells Fargo Starts Coverage on Arcellx with Bullish Outlook
Wells Fargo initiates coverage of Arcellx with an Overweight rating and a $100 price target, citing strong potential for its CAR-T therapy anito-cel in multiple myeloma.